Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising agent for preventing RSV. To evaluate the efficacy and safety of nirsevimab through a sys...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pediatrics and neonatology
Hlavní autoři:	Lien, Hsin-Chweng, Lien, Chi-Hone, Liu, Tzu-Yu, Weng, Shun-Long, Tai, Yu-Lin, Huang, Ya-Ning, Chi, Hsin, Chiu, Nan-Chang, Yeung, Chun-Yan, Lin, Chien-Yu
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Singapore Elsevier B.V 13.11.2025
Témata:	Beyfortus Internal Medicine Monoclonal antibody Nirsevimab Passive immunity Pediatrics Respiratory syncytial virus RSV Seasonality Traveller Beyfortus Respiratory syncytial virus RSV Seasonality Passive immunity Monoclonal antibody Traveller Nirsevimab passive immunity monoclonal antibody respiratory syncytial virus traveller seasonality nirsevimab
ISSN:	1875-9572, 2212-1692, 2212-1692
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!